FDA Panel Narrowly Votes Against Cough/Cold Drugs For Children Up To Age 6
This article was originally published in The Tan Sheet
Executive Summary
An FDA advisory panel decided in split votes Oct. 19 to recommend immediately that all OTC cough/cold medicines should not be used for 2-to 5-year-old children but are safe for 6- to 12-year-olds
You may also be interested in...
Televise The COVID-19 Vaccine Advisory Committee Meetings
With the meetings available on television, access can be assured for just about everyone, and the US FDA can avoid another gut punch to its credibility.
Ambitious Schedule For OTC Monograph Updates On FDA Unified Agenda
Nearly two-thirds of FDA’s planned regulatory actions for the consumer health segment would update the OTC drug monograph, including changes to pediatric cough/cold labeling, acetaminophen dosing, oral care products with benzocaine and labeling for some laxatives.
Ambitious Schedule For OTC Monograph Updates On FDA Unified Agenda
Nearly two-thirds of FDA’s planned regulatory actions for the consumer health segment would update the OTC drug monograph, including changes to pediatric cough/cold labeling, acetaminophen dosing, oral care products with benzocaine and labeling for some laxatives.